We choose indications by asking ourselves, “What problems are patients facing that need to be solved?”. Then, we use our scientific insights combined with our proprietary platform to highlight opportunities outside commonly-practiced approaches.
Spinal Muscular Atrophy and Other Myostatin-Related Disorders
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
Apitegromab (SMA)
Internal Proprietary Program
Next Anticipated Milestone: Topline 12-month results in 2Q21
Target: Pro/Latent Myostatin
Description: Spinal Muscular Atrophy (SMA)
The TOPAZ study will assess the safety and efficacy of apitegromab (SRK-015) in patients with Type 2 and Type 3
Apitegromab (Myostatin-Related Disorders)
Internal Proprietary Program
Myostatin-Related Disorders
Next Anticipated Milestone: Identify second indication for apitegromab in 2021
Target: Pro/Latent Myostatin
Description: Myostatin-Related Disorders
Oncology and Immuno-Oncology
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
SRK-181 (Context-Independent Latent TGFβ1) (Immuno-Oncology)
Internal Proprietary Program
Immuno-Oncology (Primary resistance to checkpoint inhibitor therapies)
Next Anticipated Milestone: Advance to Part B of DRAGON trial in 2Q21
Target: TGFβ1
Description: Urothelial carcinoma, melanoma, non-small cell lung cancer, amongst other solid tumor types (primary resistance to checkpoint inhibitor therapies)
SRK-181 (Context Independent Latent TGFβ1) (Oncology)
Internal Proprietary Program
Oncology
Target: TGFβ
Context-Dependent Latent TGFβ1 / Immune Cell (Oncology/Immuno-Oncology)
Internal Proprietary Program
Oncology / Immuno-Oncology
Target: Latent TGFβ1
Context-Dependent Latent TGFβ1 / GARP (Oncology/Immuno-Oncology)
In partnership with Janssen
Oncology / Immuno-Oncology
Target: Latent TGFβ1
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
Context-Independent Latent TGFβ1
In partnership with Gilead
Fibrosis
Target: Latent TGFβ1
Context-Dependent Latent TGFβ1 / LTBP1 & LTBP3
In partnership with Gilead
Fibrosis
Target: Latent TGFβ1
Undisclosed Program
In partnership with Gilead
Fibrosis
Target: Latent TGFβ
Iron-Restricted Anemias
Discovery / Preclinical
Phase 1
Phase 2
Phase 3
BMP6 Signaling Pathway (anti-RGMc)
Internal Proprietary Program
Iron-Restricted Anemias
Target: RGMc
Description: Iron-restricted
Clinical Trials
We focus on the discovery and development of safe and effective therapies to find optimal solutions for those who need it.
Partnerships
Help us shed light on the subject. Collaborate with us to uncover enlightened solutions for patients.